177Lu-DOTATATE在广泛骨病变神经内分泌肿瘤患者中的安全性与疗效
单中心回顾性分析30例广泛骨转移(>50%骨骼受累)的进展期神经内分泌肿瘤患者,接受177Lu-DOTATATE治疗,平均每周期给药活度7.308 GBq(SD 0.02),平均治疗间隔15周;估计中位无进展生存期27个月、中位总生存期35个月,3/4级骨髓毒性发生率10%,无3/4级肾毒性,总体生活质量评分改善(P=0.019)。
要点
- 广泛骨转移NET患者接受177Lu-DOTATATE后估计中位PFS为27个月、中位OS为35个月。
- 3/4级骨髓毒性发生率为10%,无患者出现3/4级肽受体放射性核素治疗相关肾毒性。
- 总体生活质量评分改善(P=0.019),延长周期间隔似乎不降低疗效并可能降低毒性。
核心结论
- 177Lu-DOTATATE对广泛骨病变的晚期转移性NET似乎具有满意的治疗结果,PFS合理且总体健康相关生活质量显著改善。
- 骨髓毒性在可接受范围内。
- 延长周期间隔似乎不降低疗效并可能降低毒性,确保骨髓在周期间有足够时间恢复。
研究设计与样本
- 单中心回顾性分析,纳入30例接受177Lu-DOTATATE治疗的进展期转移性NET患者(13例女性、17例男性,平均年龄60岁,范围35-77岁)。
- 患者基线68Ga-DOTATATE PET/CT显示广泛骨骼转移(>50%骨骼受累)。
- 平均每周期给药活度为7.308 GBq(SD 0.02),平均治疗间隔为15周。
- 进行了生存分析(无进展生存期、总生存期)、影像学反应评估、毒性评估和健康相关生活质量评估。
主要发现
- 26例患者完成4个周期,4例患者接受少于4个周期的177Lu-DOTATATE。
- 1例患者(3%)因血液学毒性未完成治疗。
- 估计中位无进展生存期为27个月,中位总生存期为35个月。
- 治疗结束时影像学评估显示部分缓解5例(17%)、疾病稳定20例(66%)、影像学疾病进展3例(10%),另有2例(7%)临床进展。
- 3/4级骨髓毒性发生率为10%,无患者出现3/4级肽受体放射性核素治疗相关肾毒性;总体生活质量评分(欧洲癌症研究与治疗组织生活质量问卷-胃肠道NET-21)改善(P=0.019)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The aim of this study was to assess the efficacy and safety of 177 Lu-DOTATATE in patients with neuroendocrine tumors (NETs) and extensive bone metastases, that is, more than 50% of the skeleton involved. METHOD: A single-center retrospective analysis was performed in 30 patients (13 women and 17 men, mean age, 60 years; range, 35-77 years) undergoing 177 Lu-DOTATATE therapy. Patients had progressive metastatic NETs with extensive skeletal metastases (>50% skeletal involvement seen on baseline 68 Ga-DOTATATE PET/CT). The average administered activity was 7.308 (SD, 0.02) GBq per cycle with average treatment interval of 15 weeks. Survival analyses (progression-free survival [PFS], overall survival), radiological response assessment, toxicity assessment, and health-related quality of life (QoL) was performed. RESULTS: Overall, 26 patients completed 4 cycles, and 4 patients had less than 4 cycles of 177 Lu-DOTATATE. One patient (3%) did not complete treatment because of hematological toxicity. The estimated median PFS and median overall survival were calculated at 27 and 35 months, respectively. End-of-treatment radiological assessment showed partial response in 5 patients (17%), stable disease in 20 patients (66%), and radiological progressive disease in 3 patients (10%). Clinical progression was seen in a further 2 patients (7%).The incidence of grade 3/4 bone marrow toxicity was 10%. No patient had grade 3/4 peptide receptor radionuclide therapy-related nephrotoxicity. There was overall improvement in global QoL score (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal NET-21) ( P = 0.019). CONCLUSION: 177 Lu-DOTATATE seems to have satisfactory therapeutic outcome in patients with advanced metastatic NET with extensive bone disease, with reasonable PFS and significant improvement in the global health-related QoL. The bone marrow toxicity was within the accepted range. Increasing the interval between cycles does not seem to reduce efficacy and may reduce toxicity, ensuring the bone marrow has sufficient time to recover between cycles.
引用
- Alsadik S, Gnanasegaran G, Chen L, et al. Safety and Efficacy of 177 Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone Disease. Clin Nucl Med. 2023. PMID: 37167406. doi:10.1097/RLU.0000000000004671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。